Jiangsu Bioperfectus Technologies Co., Ltd.

A batch of Bioperfectus-developed Nucleic Acid Extraction System SSNP-2000B began shipping today to World Health Organization (WHO). The distribution of Bioperfectus SSNP-2000B Nucleic Acid Extraction System will support the development of molecular diagnostics in Africa. Bioperfectus SSNP-2000B Nucleic Acid Extraction System is a laboratory medical device thatintegrates mechanism and electrical automation,and computer software to enable automatic nucleic acid extraction of 32 samples maximumly in one time. The instrument won theworld-renowned iF DESIGN AWARD 2022in recognition of its unique structure and innovative design. During the COVID-19 pandemic, Bioperfectus supported WHO in responding to the COVID-19 crisis by delivering test kits and training for health professionals worldwide. Bioperfectus is proud to continue collaborating with WHO as an IVD supplier in molecular diagnostic projects. Molecular diagnostics plays a vital role in infectious disease detection, case management, surveillance, and a supporting role in therapeutic and vaccine trials. Bioperfectus is committed to providing laboratories with more efficient and accurate diagnosis solutions. SSNP series, as an important part of the Bioperfectus extraction product portfolio, allows customers to have more flexible choices based on their sample throughput. Three SSNP extraction systems of different throughputs provide multiple choices for the laboratory. The optional throughputs vary from 32 to 96 channels. With pre-programmed protocols and pre-filled kits, it is very easy and highly efficient to operate. And it only takes less than 15 minutes to complete the extraction process.All models are equipped with HEPA filter-independent air path in which the biological filter cotton can absorb the nucleic acid aerosol. Bioperfectus provides a total PCR solution with automated instruments and abundant reagent panels. Total PCR solution will help you automate your lab, free up human labor and save costs. Pioneering in molecular diagnostics, Bioperfectus is always devoted to pursuing high quality, innovating, and striving to solve health problems humanity faces for a healthier future.

SHANGHAI, CHINA, December 5, 2022Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as Bioperfectus) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance. Cholera is an acute diarrheal infection caused by ingestion of food or water contaminated with the bacterium Vibrio cholerae. There are many serogroups of V. cholerae, but only two O1 and O139 cause outbreaks. V. cholerae O1 has caused all recent outbreaks. About 20% of those who are infected with V. cholerae develop acute watery diarrhea; approximately 20% of these individuals develop severe watery diarrhea, many also with vomiting. If these patients are not promptly and adequately treated, the loss of fluid and salts can lead to severe dehydration and death within hours. The case fatality rate in untreated cases may be 3050%. Researchers have estimated that each year there are 1.3 to 4.0 million cases of cholera and 21 000 to 143 000 deaths worldwide due to cholera. Cholera remains a global threat to public health and an indicator of inequity and lack of social development. Bioperfectus provides Vibrio Cholerae Real Time PCR Kits including ONE kit for human diagnosis with a CE certificate and ONE kit for environmental surveillance use to support early detection of Vibrio cholerae infection and improve early warning surveillance. Both of them are based on real-time PCR technology, for the detection of DNA from Vibrio Cholerae O1, Vibrio Cholerae O139 and Vibrio Cholerae. V. cholerae spreads through water contaminated with feces. The aquatic environment, especially surface waters and stored drinking water, is a key component of the cholera transmission chain. To date, sampling of V. cholerae in environmental and/or sewage water has been used in different contexts applying various methods. To distinguish non-toxigenic environmental strains from toxigenic strains circulating during an outbreak, identification should include O1 serogroup determination and be completed by Polymerase Chain Reaction (PCR) identification of the cholera toxin genes. The combination use of these two products can highly improve efficiency from prevention to early detection, to narrow the transmission scale as early as possible. Bioperfuctus, a one-stop supplier specializing in molecular diagnostics, highly recommends the Total PCR Solution for Gastrointestinal Infectious disease, with higher throughput and higher efficiency. Dedicated to providing laboratories with comprehensive tests of Gastrointestinal Infectious disease, Bioperfectus provides the 𝐓𝐨𝐭𝐚𝐥 𝐏𝐂𝐑 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 with instruments and kits. Pioneering in molecular diagnostic, Bioperfectus are always devoted to pursuing high quality, keeps innovating, and strives to solve health problems faced by humankind for a healthier future. 𝖱𝖾𝖿𝖾𝗋𝖾𝗇𝖼𝖾: [𝟣] https://www.who.int/news-room/fact-sheets/detail/cholera?gclid=Cj0KCQiAj4ecBhD3ARIsAM4Q_jH7qVKuIvE3-gFOip6hkAoJmCbYeoQSQiNYE34jQoI7LlkKUDZDe_EaArgtEALw_wcB [2]https://www.gtfcc.org/wp-content/uploads/2022/10/gtfcc-technical-note-environmental-surveillance-for-cholera-control-october-2022.pdf

In December 2021, the world faced a new outbreak with the COVID-19 Omicron variant,which triggered another chapter in the COVID-19 pandemic. The highly transmissible Omicron variant of COVID-19 has been driving an unprecedented surge of infections globally. With the rise of the omicron variant, the ability of diagnostic tests to detect the Omicron variant was critical to tracking its spread and putting measures to halt transmission in place.PCR tests are accurate but can take a long time to produce results. Antigen tests, the other primary type of coronavirus test, offer the advantage of producing results much more quickly. Antigen tests are quick and easy diagnostic tests to identify patients infected with SARS-CoV-2.The Israeli ministry of health aimed to make antigen rapid tests available as a screening tool for Israeli citizens, reduce community transmission, and keep the economy running. The Israeli ministry of health urgently needed to find potential IVD suppliers to offer antigen rapid test kits that meet high quality and global regulatory standards. Earlyin the omicron surge,many manufacturers' antigen rapid test kits had a limited ability to detectOmicroninfections, and rapid antigen testsmay be spitting out false positives. Based on the excellent cooperation and trust between Bioperfectus and the Israeli distributor, Bioperfectus received an urgent request from the distributor to participate in a tender for Novel Corona Virus antigen rapid test kits. As required by the Israeli ministry of health, the supplier must provide sufficient clinical evidence on the antigen rapid test kit and assist the Israeli ministry of health in conducting the clinical evaluation, which ensures that test kits can detect the Omicron virus accurately. Through a critical assessment of clinical evaluation and data validation, Bioperfectus successfully passed the Israeli ministry of health inspection. Bioperfectus was the only Chinese company on the procurement list and was asked to provide two million antigen rapid test kits for the Israeli ministry of health. The Bioperfectus production department immediately deployed a team to take charge of this task, given the highest priority andurgency, working closely with the supply chain and warehouse management team, from raw material procurement to production and packaging. With Lunar New Yearapproaching, the production department organized the plan and kept production running smoothly and effectively. At the same time, the international business team coordinated and supported different departments to ensure supplies were delivered on time. Another challenge Bioperfectus faced was the issue of international logistics. The major international airlines were disrupted due to the spread of the omicron variant. The international business team created a flexible solution to deliver two million test kits to Israel in three batches within the deadline. It's a race against time. Greatteams worktogether toaccomplishthe great result. The team leader of the international business department said. More critical for Bioperfectus is to support the Israeli authorities in response to the Omicron variant and protect local people.